Q32 Bio reports Q1 2026 net loss of $7.6M; bempikibart trial on track for mid-2026 data

Q32 Bio Inc.

2026-Q1 EPS reported -$0.54

Cash $50.8M at Mar 31; plus $14.2M ATM proceeds post-Q and milestone payments fund into 1H 2028.
Net loss $7.6M ($0.54 EPS) vs $11.0M ($0.90) in Q1 2025.
Bempikibart Part B SIGNAL-AA 36-wk topline data readout on track for mid-2026; first OLE patient dosed.
Completed $10.5M registered direct offering in Feb 2026 (1.7M shares/pre-funded warrants at $3.90).
R&D expenses fell to $3.2M from $7.1M due to headcount reduction and ADX-097 sale.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Q32 Bio Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $7.6 million, or $0.54 basic and diluted net loss per share, EPS $0.54 basic and diluted net loss per share.

Period: the quarter ended March 31, 2026
Net income: Net loss was $7.6 million, or $0.54 basic and diluted net loss per share
EPS: $0.54 basic and diluted net loss per share
Result: reported results

Exact text from the filing

Net loss was $7.6 million, or $0.54 basic and diluted net loss per share, for the three months ended March 31, 2026, compared to net loss of $11.0 million, or $0.90 basic and diluted net loss per share, for the three months ended March 31, 2025.

View on SEC.gov

Browse all earnings releases →

Q32 Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-205006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.